Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL25169871

COc1ccc(CN(CCOP(=O)(O)O)C(=O)CCCCc2cccc(OCCc3ccc(-c4ccccc4)cc3)c2)cc1.N

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 5/20 0.51
▸ SLC2A4 P14672 2/20 0.48
▸ SLC2A8 Q9NY64 1/20 0.47
▸ NR1H3 Q13133 2/20 0.44
▸ ALOX5 P09917 1/20 0.44
▸ LPAR1 Q92633 3/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ S1PR1 P21453 3/20 0.42
▸ S1PR3 Q99500 3/20 0.42
▸ S1PR4 O95977 2/20 0.42
▸ S1PR5 Q9H228 2/20 0.42
▸ PTGDR2 Q9Y5Y4 1/20 0.42
▸ RAF1 P04049 2/20 0.42
▸ MAP2K1 Q02750 2/20 0.42
▸ FFAR1 O14842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25456779 0.99 SLC2A1 (0.51) SLC2A1SLC2A4SLC2A8NR1H3ALOX5
Ammonia Solution, Strong SCHEMBL25173211 0.97 SLC2A1 (0.47) SLC2A1SLC2A4SLC2A8NR1H3ALOX5
SCHEMBL25456761 0.93 SLC2A1 (0.51) SLC2A1SLC2A4SLC2A8NR1H3ALOX5
Ammonia Solution, Strong SCHEMBL25169992 0.93 S1PR1 (0.48) SLC2A1ALOX5LPAR1NPC1LMNA
SCHEMBL25456787 0.92 S1PR1 (0.49) SLC2A1ALOX5LPAR1NPC1LMNA
SCHEMBL25456788 0.92 ALOX5 (0.48) ALOX5LPAR1S1PR1S1PR3S1PR4
Ammonia Solution, Strong SCHEMBL25167618 0.91 S1PR1 (0.51) ALOX5LPAR1NPC1LMNAALOX15
SCHEMBL25456789 0.90 S1PR1 (0.51) ALOX5LPAR1NPC1LMNAALOX15
Ammonia Solution, Strong SCHEMBL25170014 0.89 SLC2A1 (0.49) SLC2A1SLC2A4SLC2A8NR1H3ALOX5
Ammonia Solution, Strong SCHEMBL25175635 0.88 ALOX5 (0.52) ALOX5LPAR1NPC1LMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 — — US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 SLC2A1 3997/4885SLC2A4 2684/4885SLC2A8 3870/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 SLC2A1 3980/4885SLC2A4 2668/4885SLC2A8 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback